Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease.

@article{Zesiewicz2006OpenlabelPS,
  title={Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease.},
  author={Theresa Ann Zesiewicz and Kelly L. Sullivan and Robert A. Hauser and Juan Sanchez-Ramos},
  journal={Movement disorders : official journal of the Movement Disorder Society},
  year={2006},
  volume={21 11},
  pages={1998-2001}
}
The objective of this study is to evaluate the tolerability and preliminary efficacy of levetiracetam (LEV) in reducing chorea in Huntington's disease (HD) patients in a prospective open-label pilot study. Nine HD patients with chorea were treated with LEV in doses up to 3,000 mg/day for up to 48 days. The primary endpoint measure was the Unified Huntington's Disease Rating Scale (UHDRS) chorea subscore. The mean dose (+/-SD) of LEV at endpoint was 2,583.3 +/- 1,020.6 mg/day. Mean UHDRS chorea… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

Similar Papers

Loading similar papers…